Distinct origins and transmission pathways of bla_KPC Enterobacterales across three U.S. states

Competing Interest Statement

M.K.H. was a member of a clinical adjudication panel for an investigational SARS-CoV-2 vaccine developed by Sanofi for a year and a half, ending in July 2022.

Funding Statement

This work was supported by the CDC through the Emerging Infections Program cooperative agreement (grant number CK17-1701). It was also supported in part by CDC Prevention Epicenter Program Cooperative Agreement No. U54CK000481-S1. ZL received support from the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE 1256260. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the Tennessee Department of Health institutional review board (IRB). See 45 CFR. part 46; 21 CFR part 56. The Minnesota and Connecticut Department of Health IRB determined that the study was exempt from IRB review in accordance with 45 CFR 46.101(b)(4).” The study was approved by the CDC IRB with a waiver of HIPAA authorization under the Privacy Rule as per 45 CFR 46.512(i). The University of Michigan Medical School IRB approved this protocol.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes